185 related articles for article (PubMed ID: 9495240)
1. Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity.
Farina AR; Coppa A; Tiberio A; Tacconelli A; Turco A; Colletta G; Gulino A; Mackay AR
Int J Cancer; 1998 Mar; 75(5):721-30. PubMed ID: 9495240
[TBL] [Abstract][Full Text] [Related]
2. Retinoic acid-enhanced invasion through reconstituted basement membrane by human SK-N-SH neuroblastoma cells involves membrane-associated tissue-type plasminogen activator.
Tiberio A; Farina AR; Tacconelli A; Cappabianca L; Gulino A; Mackay AR
Int J Cancer; 1997 Nov; 73(5):740-8. PubMed ID: 9398056
[TBL] [Abstract][Full Text] [Related]
3. Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta.
Shiou SR; Datta PK; Dhawan P; Law BK; Yingling JM; Dixon DA; Beauchamp RD
J Biol Chem; 2006 Nov; 281(45):33971-81. PubMed ID: 16959768
[TBL] [Abstract][Full Text] [Related]
4. Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells.
Arnoletti JP; Albo D; Granick MS; Solomon MP; Castiglioni A; Rothman VL; Tuszynski GP
Cancer; 1995 Sep; 76(6):998-1005. PubMed ID: 8625226
[TBL] [Abstract][Full Text] [Related]
5. Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells.
Festuccia C; Angelucci A; Gravina GL; Villanova I; Teti A; Albini A; Bologna M
Int J Cancer; 2000 Feb; 85(3):407-15. PubMed ID: 10652434
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
7. CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activity.
Montgomery N; Hill A; McFarlane S; Neisen J; O'Grady A; Conlon S; Jirstrom K; Kay EW; Waugh DJ
Breast Cancer Res; 2012 May; 14(3):R84. PubMed ID: 22621373
[TBL] [Abstract][Full Text] [Related]
8. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin.
Festuccia C; Guerra F; D'Ascenzo S; Giunciuglio D; Albini A; Bologna M
Int J Cancer; 1998 Jan; 75(3):418-31. PubMed ID: 9455804
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor beta 1 and sodium butyrate differentially modulate urokinase plasminogen activator and plasminogen activator inhibitor-1 in human breast normal and cancer cells.
Dong-Le Bourhis X; Lambrecht V; Boilly B
Br J Cancer; 1998; 77(3):396-403. PubMed ID: 9472634
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human MDA-MB-231 breast cancer cell invasion by matrix metalloproteinase 3 involves degradation of plasminogen.
Farina AR; Tacconelli A; Cappabianca L; Gulino A; Mackay AR
Eur J Biochem; 2002 Sep; 269(18):4476-83. PubMed ID: 12230559
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor beta1 stimulates urokinase plasminogen activator system on prostate cancer cells.
Unlü A; Leake RE
Int J Biol Markers; 2003; 18(2):147-51. PubMed ID: 12841684
[TBL] [Abstract][Full Text] [Related]
13. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
14. TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression.
Sugioka K; Kodama A; Okada K; Iwata M; Yoshida K; Kusaka S; Matsumoto C; Kaji H; Shimomura Y
Exp Eye Res; 2013 Oct; 115():13-21. PubMed ID: 23810810
[TBL] [Abstract][Full Text] [Related]
15. (-)-Epigallocatechin gallate derivatives reduce the expression of both urokinase plasminogen activator and plasminogen activator inhibitor-1 to inhibit migration, adhesion, and invasion of MDA-MB-231 cells.
Shin S; Kim MK; Jung W; Chong Y
Phytother Res; 2018 Oct; 32(10):2086-2096. PubMed ID: 30009577
[TBL] [Abstract][Full Text] [Related]
16. Critical involvement of ILK in TGFbeta1-stimulated invasion/migration of human ovarian cancer cells is associated with urokinase plasminogen activator system.
Lin SW; Ke FC; Hsiao PW; Lee PP; Lee MT; Hwang JJ
Exp Cell Res; 2007 Feb; 313(3):602-13. PubMed ID: 17187779
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor beta1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa.
Pasini FS; Brentani MM; Kowalski LP; Federico MH
Head Neck; 2001 Sep; 23(9):725-32. PubMed ID: 11505481
[TBL] [Abstract][Full Text] [Related]
18. Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator.
Shi C; Zhang N; Feng Y; Cao J; Chen X; Liu B
Cell Physiol Biochem; 2017; 41(4):1313-1324. PubMed ID: 28278500
[TBL] [Abstract][Full Text] [Related]
19. Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells.
Ree AH; Bjørnland K; Brünner N; Johansen HT; Pedersen KB; Aasen AO; Fodstad O
Clin Exp Metastasis; 1998 Apr; 16(3):205-15. PubMed ID: 9568638
[TBL] [Abstract][Full Text] [Related]
20. Detection of matrix metalloproteinases (MMP), tissue inhibitor of metalloproteinase-2, urokinase and plasminogen activator inhibitor-1 within matrigel and growth factor-reduced matrigel basement membrane.
Gillette KM; Forbes K; Sehgal I
Tumori; 2003; 89(4):421-5. PubMed ID: 14606648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
